| |
| |
| Editors and Contributors | |
| |
| |
| Foreword | |
| |
| |
| Preface | |
| |
| |
| How well do various lipids and lipoprotein measures predict cardiovascular disease morbidity and mortality? | |
| |
| |
| Framingham risk scoring or risk factor counting: which is more sensitive and how do I use this information to determine patient-specific lipid goals? | |
| |
| |
| What is the metabolic syndrome, how do I treat it and is it a high-risk condition? | |
| |
| |
| Should all patients admitted to the hospital with an acute coronary syndrome initiate statin therapy? | |
| |
| |
| What are CAD risk equivalents and how did these clinical entities come to be so defined? | |
| |
| |
| When should children and adolescents be screened for dyslipidemia and how should they be treated? | |
| |
| |
| Management of dyslipidemia in women | |
| |
| |
| In high and very high-risk patients, is it true that when it comes to LDL-c, lower is better and can a serum LDL-c be driven too low? | |
| |
| |
| How should we approach to statin-treated patient with myalgia? | |
| |
| |
| Pleiotropic effects of statins and their relevance to cardiovascular outcomes | |
| |
| |
| An update on the 'rubber chicken' treatment of dyslipidemia: therapeutic lifestyle change and the alphabet soup of behavior modification | |
| |
| |
| What is the best place for fibrate therapy in reducing cardiovascular risk? | |
| |
| |
| Niacin for dyslipidemia management and atheroprevention: why, when and how? | |
| |
| |
| Which dietary supplements have proven efficacy for impacting serum lipids and cardiovascular outcomes and are any vitamins harmful to the cardiovascular system? | |
| |
| |
| Why do lipid-lowering agents affect serum transaminase levels, are these drugs toxic to the liver and can they precipitate liver failure? | |
| |
| |
| Should we treat a low serum HDL-c and what specific lifestyle changes and drugs can be used to raise a low HDL-c? | |
| |
| |
| What is familial hypercholesterolemia and how should it be treated? | |
| |
| |
| Should plasma levels of lipoprotein(a) be measured? Guiding principles from bench to bedside | |
| |
| |
| Clinical utilization of advanced lipid testing | |
| |
| |
| Should we treat dyslipidemia in the elderly and is there an upper age limit to instituting lipid-lowering therapy? | |
| |
| |
| List of abbreviations | |
| |
| |
| Index | |
